Other Income & Expense
Change in Net Unrealized Gains (Losses) on AFS Securities
Year-over-year, this metric declined by 847.1%, from $1.70M to -$12.70M. Over 3 years (FY 2021 to FY 2025), Change in Net Unrealized Gains (Losses) on AFS Securities shows an upward trend with a 0.0% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
First reportedQ1 2018
Last reportedQ1 2026May 5, 2026
Metric ID:
ms_unrealized_gains_losses_afs_securitiesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$300.00K | -$300.00K | -$2.10M | -$7.60M | -$2.90M | -$1.80M | $4.00M | $700.00K | $800.00K | $7.00M | -$3.20M | -$900.00K | $9.10M | -$5.10M | $1.70M | $2.70M | -$900.00K | $0.00 | -$12.70M |
| QoQ Change | — | +0.0% | -600.0% | -261.9% | +61.8% | +37.9% | +322.2% | -82.5% | +14.3% | +775.0% | -145.7% | +71.9% | >999% | -156.0% | +133.3% | +58.8% | -133.3% | +100.0% | — |
| YoY Change | — | — | — | — | -866.7% | -500.0% | +152.6% | +124.1% | +144.4% | — | -180.0% | -228.6% | >999% | -172.9% | +153.1% | +400.0% | -109.9% | +100.0% | -847.1% |
Range-$12.70M – $9.10M
CAGR+129.9%
Avg YoY Growth-56.7%
Median YoY Growth-4.9%
Change in Net Unrealized Gains (Losses) on AFS Securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's change in net unrealized gains (losses) on afs securities?
- Neurocrine Biosciences (NBIX) reported change in net unrealized gains (losses) on afs securities of -$12.70M in Q1 2026.
- How has Neurocrine Biosciences's change in net unrealized gains (losses) on afs securities changed year-over-year?
- Neurocrine Biosciences's change in net unrealized gains (losses) on afs securities decreased by 847.1% year-over-year, from $1.70M to -$12.70M.
- What is the long-term trend for Neurocrine Biosciences's change in net unrealized gains (losses) on afs securities?
- Over 3 years (2021 to 2025), Neurocrine Biosciences's change in net unrealized gains (losses) on afs securities has grown at a 0.0% compound annual growth rate (CAGR), from -$3.50M to $3.50M.